Sign in

Xin Chen

Research Analyst at UBS Asset Management Americas Inc.

Xin Chen is an Executive Director and Equity Research Analyst at UBS Group AG, specializing in the U.S. biotechnology sector. He covers a range of leading biotech companies including Amgen, Gilead Sciences, Regeneron, and Biogen, and is known for delivering timely and accurate investment insights that have achieved success rates near 70% and above-average returns according to leading analyst ranking platforms. Xin Chen began his career as a research associate at Credit Suisse, later moving to Oppenheimer & Co. before joining UBS in 2016, quickly advancing to his current senior role. He holds FINRA Series 7, 63, and 86/87 licenses, and his analytical acumen and sector expertise have been recognized among top biotechnology analysts on TipRanks.

Xin Chen's questions to Atour Lifestyle Holdings (ATAT) leadership

Question · Q2 2025

Xing Chen from UBS Group asked for an update on the 2025 guidance for hotel openings and closures, the recent trend in franchise signings, and whether increasing market competition will affect future development plans.

Answer

Management confirmed its confidence in achieving the full-year guidance of 500 new hotel openings and reaching a total of 2,000 hotels. They anticipate 70 to 80 hotel closures for the full year as part of an active replacement strategy to maintain quality. Despite market turbulence, the company will adhere to high standards for new signings, prioritizing quality growth and long-term value for franchisees over sheer scale.

Ask follow-up questions

Fintool

Fintool can predict Atour Lifestyle Holdings logo ATAT's earnings beat/miss a week before the call

Question · Q2 2025

Xing Chen from UBS Group AG asked if there were any changes to the 2025 guidance for hotel openings and closures, questioned the recent trend in franchise signings amid market competition, and inquired if this would affect future development plans.

Answer

CEO Wang Haijun (via moderator) affirmed confidence in meeting the full-year guidance of 500 new hotel openings and reaching a total of 2,000 hotels. He noted 34 closures in H1 and projected 70-80 for the full year to maintain quality standards. Despite market turbulence, the company will uphold high standards for new signings, prioritizing precise location selection and quality over scale, adhering to its long-termist development philosophy.

Ask follow-up questions

Fintool

Fintool can write a report on Atour Lifestyle Holdings logo ATAT's next earnings in your company's style and formatting

Question · Q4 2024

Xin Chen from UBS asked for an update on the strategy for Atour's high-end brands, Atour S and Sakura, and inquired about the recent performance of the Atour Light 3.0 brand.

Answer

CEO Haijun Wang stated that the upscale Atour S and Sakura brands are developing in parallel, with the first Sakura hotel in Shanghai receiving high praise since its opening. Regarding Atour Light 3.0, he confirmed its development is aligned with expectations, having expanded to over 100 hotels with strong operational performance and another 100+ in the pipeline, boosting franchisee confidence.

Ask follow-up questions

Fintool

Fintool can auto-update your Excel models when Atour Lifestyle Holdings logo ATAT reports

Question · Q2 2024

Xin Chen from UBS inquired about the company's RevPAR performance trends since July, the outlook for full-year 2024 RevPAR, and the expected full-year profit margin given the shifts in the group's revenue structure.

Answer

Founder, Chairman and CEO Haijun Wang acknowledged a high comparison base from last summer but expressed confidence in performance, noting same-hotel RevPAR is expected to outperform the group's blended rate. He raised the full-year revenue growth guidance to a range of 48% to 52% year-over-year and projected the full-year adjusted net profit margin would remain at approximately 18%.

Ask follow-up questions

Fintool

Fintool can alert you when Atour Lifestyle Holdings logo ATAT beats or misses

Let Fintool AI Agent track Xin Chen for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free